சுருக்கம்

Emerging treatment in Anemia in myelofibrosis

Samer Omer

A clonal hematologic malignancy called myelofibrosis causes progressive bone marrow fibrosis. Splenomegaly, constitutional symptoms, and anaemia are some of the clinical signs of MF. Anemia has a complex pathophysiology and is clinically linked to poor quality of life and worse overall survival. Allogenic stem cell transplantation is the sole curative therapy for MF, however only a small number of individuals are suitable. The efficacy of disease treatment techniques for MF-related anaemia is limited, and Janus kinase inhibitors may cause or exacerbate the condition. As a result, there is a big unmet need in the field of treating MF-related anaemia patients. This review discusses existing and novel therapies for anaemia in MF, such as momelotinib and pacritinib JAK inhibitors, luspatercept and KER-050 transforming growth factor-ligand traps, and pelabresib, a bromodomain extra-terminal domain inhibitor.